Publications

Cayrol F, Revuelta MV, Debernardi M, Paulazo A, Phillip JM, Zamponi N, Sterle H, Flaqué MCDíaz, Magro C, Marullo R et al..  2022.  Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.. Mol Cancer Ther. 21(9):1485-1496.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al..  2020.  Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Cayrol F, Flaque MCDiaz, Fernando TM, Yang S-N, Cerchietti L, Cremaschi G.  2015.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood. 125(5):841-851.

Tian YF, Ahn H, Schneider RS, Yang SNing, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.  2015.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.. Biomaterials. 73:110-9.

Ruan J, Luo M, Wang C, Fan L, Yang SNing, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L et al..  2013.  Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.. Blood. 121(26):5192-202.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SNing, Reiter A, Siebert R, Melnick A et al..  2011.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.. PLoS One. 6(4):e18436.

Diament MJudith, Peluffo GDaniel, Stillitani I, Cerchietti LCarlos, Navigante A, Ranuncolo SMaris, Klein SMariana.  2006.  Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. Cancer Invest. 24(2):126-31.